Trials / Not Yet Recruiting
Not Yet RecruitingNCT06647329
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological and Lymphatic Tumors: Multi-Center Clinical Study on Safety and Efficacy
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Mingzhi Zhang · Academic / Other
- Sex
- All
- Age
- 14 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
evaluate the safety and Esfficacy of CAR-T technology for the treatment of recurrent/refractory malignant hematological lymphomas
Detailed description
Patients with recurrent/refractory malignant hematological lymphomas were treated with CAR-T technology
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR-T Therapy | CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological Lymphomas |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2024-10-17
- Last updated
- 2024-10-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06647329. Inclusion in this directory is not an endorsement.